•							
1	TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION	Docket No. PG4709					
	In re Application of: BIGGADIKE, et. al. Application No. 10/066,964 Filed: 02/04/2002 For: FORMULATION CONTAINING NOVEL ANTI-INCLASSING TORY ANDROSTAN	/ 4 ³ TE DERIVATIVES					
	The owner, SmithKline Beecham Corporation of interest in the instant application hereby disclaims, except as provided below, the terminal any patent granted on the instant application, which would extend beyond the expiration of defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior granted on pending second Application Number 09/958,050, filed on The owner hereby agrees that any patent so granted on the instant application shall be ensuch period that it and any patent granted on the second application are commonly owner any patent granted on the instant application and is binding upon grantee, its successors or	l part of the statutory term of date of the full statutory term to the grant of any patent g 10/02/2001 forceable only for and during d. This agreement runs with					
	In making the above disclaimer, the owner does not disclaim the terminal part of any properties application that would extend to the expiration date of the full statutory term as defined in 30 of any patent granted on the second application, as shortened by any terminal disclaimer from the event that any such granted patent: expires for failure to pay a maintenance fee, is invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminall 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any material expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its g	5 U.S.C. 154 to 156 and 173 filed prior to the patent grant held unenforceable, is found by disclaimed under 37 CFF unner terminated prior to the					
	Check either box 1 or 2, if appropriate.						
	1. For submissions on behalf of an organization (e.g., corporation, partners agency, etc.), the undersigned is empowered to act on behalf of the organization	hip, university, governmen on.					
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made or information and belief are believed to be true; and further that these statements were made with the knowledge tha willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 or Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.						
	2.						
	3. Owner/applicant is ☐ Small entity ☒ Large entity						
1	The terminal disclaimer fee under 37 CFR 1.20(d) is \$\frac{\$110.00}{}\$ and is to \$\frac{1}{2}\$.	be paid as follows:					
	☐ A check in the amount of the fee is enclosed.						
	The Director is hereby authorized to charge any fees which may be required, or cred to Deposit Account Number	lit any overpayment,					
	manage of the contract of the following contract of the contra						

PTO suggested wording for terminal disclaimer was

 $oxed{oxed}$ unchanged. $oxed{oxed}$ changed (if changed, an explanation should be supplied.)

Dated:

Name and Address of Person Signing

James P. Riek

Registration No.: 39,009

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive

PO Box 13398

Research Triangle Park, NC 27709

Telephone No.: 919-483-8022 Fax No.:919-483-7988

31 July 2005

I certify that this document and fee is being deposited on **9/1 /03** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Perfor Mailing Correspondence

Ban Younan

Typed or Printed Name of Person Mailing Correspondence

08/07/2003 WABDELR1 00000013 071392 10066964

03 FC:1814

110.00 DA

TERMINAL DISCLAIMER TO OBVIATE A PROVISION	IAL DOUBLE	Docket No. RECA				
TATENTING RESERVICE OVER A PENDING SECOND AT LEGATION PG4709						
In re Application of: BIGGADIKE, et. al.	4.	TECH CENTED				
· · ·	6 0 0 0	TECH CENTER 18				
Filed: 02/04/2002	6 0 6 2003 S	PCH CFNTCZ				
	FORV AND OCTAN	E DEDIVATIVES				
For: FORMULATION CONTAINING NOVEL ANTI-INFLAMNAT	LOEMARK BORUSTAN	E DERIVATIVES 293				
The owner, SmithKline Beecham Corporation	of	100.00 percent				
interest in the instant application hereby disclaims, except as provide	d below, the termina	part of the statutory term of				
any patent granted on the instant application, which would extend be	vond the expiration of	late of the full statutory term				
defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal granted on pending second Application Number 10/066.951	disciaimer filed prior	10 the grant of any patent g				
granted on pending second Application Number $10/066,951$ The owner hereby agrees that any patent so granted on the instant approximation $10/066,951$	pplication shall be en	forceable only for and during				
such period that it and any patent granted on the second application	are commonly owne	d. This agreement runs with				
any patent granted on the instant application and is binding upon grant	ee, its successors or	assigns.				
In making the above disclaimer, the owner does not disclaim the te	rminal part of any p	atent granted on the instant				
application that would extend to the expiration date of the full statutory of any patent granted on the second application, as shortened by any	term as defined in 3	iled prior to the patent grant.				
in the event that any such granted patent; expires for failure to pay a	maintenance fee, is	held unenforceable, is found				
invalid by a court of competent jurisdiction, is statutorily disclaimed 1.321, has all claims cancelled by a reexamination certificate, is rei	in whole or terminal	y disclaimed under 37 CFR				
expiration of its full statutory term as shortened by any terminal disclaim	mer filed prior to its g	rant.				
Check either box 1 or 2, if appropriate.						
Check either box 1 of 2, if appropriate.						
1.	corporation, partners	hip, university, government				
agency, etc.), the undersigned is empowered to act on be	nair or the organization	on.				
I hereby declare that all statements made herein of my own knowl	edge are true and t	hat all statements made on				
information and belief are believed to be true; and further that these willful false statements and the like so made are punishable by fine	statements were man	ade with the knowledge that both under Section 1001 of				
Title 18 of the United States Code and that such willful statements ma	ay jeopardize the vali	dity of the application or any				
patent issued thereon.						
2. The undersigned is an attorney of record.						
3. Owner/applicant is ☐ Small entity ☒ Large ent	ity					
The terminal disclaimer fee under 37 CFR 1.20(d) is\$110.0	00 and is to l	pe paid as follows:				
☐ A check in the amount of the fee is enclosed.						
- A check in the amount of the fee is enclosed.						
The Director is hereby authorized to charge any fees which may to Deposit Account Number 07-1392	be required, or cred	it any overpayment,				
PTO suggested wording for terminal disclaimer was						
□ changed (if changed, an explanation □	on should be supplied	d.)				
Dated:	31 July 2003					
Signature	51 347 213					
News and Address of Berson Signing		ument and fee is being deposited				
James P. Rick	first class mail under 37	with the U.S. Postal Service as C.F.R. 1.8 and is addressed to the				
Registration No.: 39,009	Commissioner for Pater 22313-1450.	nts, P.O. Box 1450, Alexandria, VA				
GlaxoSmithKline	1 a .	,				
Corporate Intellectual Property						
Five Moore Drive	Signature of P	son Mailing Correspondence				
PO Box 13398						
Research Triangle Park, NC 27709		an Younan				
Telephone No.: 919-483-8022 Fax No.:919-483-7988	Typed or Printed Name	of Person Mailing Correspondence				

P26/REV01

								
	al Disclaimer To Obviate A iting Rejection Over A Prior:		·		Docket No. PG4709			
	0	10						
In Re Application Of: BIGGADIKE, et. al.								
Serial No.	Filing Date	A SIX STREET	Examiner		Group Art Unit			
10/066,964	02/04/2002	Ans	BADIO		1616			
Invention: FORMULATION CONTAINING NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES								
					RECEIVED AUG 0 8 2003 TECH CENTER 1600/2900			
Owner of Record:					Alls 0 8 2000			
SmithKline Beecham Cor	poration				Trou			
					TECH CENTER 1600/2900			
	TO THE COMMISSI	ONER FO	R PATENTS:					
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,537,983. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under								
Terminal disclaimer fee under 37 C.F.R. 1.20(d) included. PTO suggested wording for terminal disclaimer was unchanged.								
Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.								

Copyright 1997 LegalStar

P32/REV01